Contineum Therapeutics (CTNM) Current Leases (2023 - 2026)

Contineum Therapeutics' Current Leases history runs 4 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Current Leases rose 58.28% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 58.28% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 61.23% from the prior year.
• Current Leases slipped to $2.3 million in Q1 2026 per CTNM's latest filing, from $2.3 million in the prior quarter.
• Across five years, Current Leases topped out at $2.3 million in Q4 2025 and bottomed at $464000.0 in Q4 2023.
• The 4-year median for Current Leases is $1.5 million (2024), against an average of $1.3 million.
• Across the five-year window, Current Leases surged 212.93% in 2024 and surged 58.28% in 2026, its largest moves.
• Year by year, Current Leases stood at $464000.0 in 2023, then jumped by 212.93% to $1.5 million in 2024, then soared by 61.23% to $2.3 million in 2025, then declined by 1.62% to $2.3 million in 2026.
• Per Business Quant, the three latest CTNM Current Leases figures stand at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $1.5 million (Q3 2025).